Combining therapies to prevent drug resistance in lung cancer
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
This study is looking for better ways to help people with advanced lung cancer by testing new combination treatments that focus on specific genetic changes in their tumors, so they can live longer without their cancer getting worse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10923865 on NIH RePORTER |
What this research studies
This research investigates how to improve treatment outcomes for patients with advanced lung cancer by developing combination therapies that target specific genetic mutations. The approach includes using precision therapies like EGFR and ALK inhibitors, alongside innovative methods to analyze tumor DNA from patients. By integrating laboratory studies with clinical trials, the research aims to find more effective treatment strategies that could extend the time patients live without disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced non-small cell lung cancer who have specific genetic mutations such as EGFR or ALK.
Not a fit: Patients with lung cancer that does not have the targeted genetic mutations or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to longer-lasting treatment responses and improved survival rates for lung cancer patients.
How similar studies have performed: Previous research has shown promising results with combination therapies in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Janne, Pasi a — Dana-Farber Cancer Inst
- Study coordinator: Janne, Pasi a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.